Medtronic plc. (NYSE:mdt) declared a quarterly dividend on Friday, March 10th. Shareholders of record on Friday, March 24th will be given a dividend of 0.43 per share by the medical technology company on Thursday, April 13th. This represents a $1.72 dividend on an annualized basis and a yield of 2.11%. The ex-dividend date of this dividend is Wednesday, March 22nd.
Medtronic plc. (NYSE:MDT) opened at 81.42 on Tuesday. The firm’s 50-day moving average is $79.29 and its 200-day moving average is $79.49. The stock has a market capitalization of $111.45 billion, a P/E ratio of 28.74 and a beta of 0.97. Medtronic plc. has a 12-month low of $69.35 and a 12-month high of $89.27.
Medtronic plc. (NYSE:MDT) last announced its earnings results on Tuesday, February 21st. The medical technology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.01. The company earned $7.28 billion during the quarter, compared to the consensus estimate of $7.22 billion. Medtronic plc. had a return on equity of 12.36% and a net margin of 14.63%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 earnings per share. Analysts predict that Medtronic plc. will post $4.58 EPS for the current fiscal year.
In related news, CEO Omar Ishrak sold 95,000 shares of the stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $82.82, for a total transaction of $7,867,900.00. Following the sale, the chief executive officer now directly owns 645,616 shares of the company’s stock, valued at $53,469,917.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Hooman Hakami sold 52,316 shares of the stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $82.33, for a total value of $4,307,176.28. Following the sale, the executive vice president now directly owns 73,800 shares in the company, valued at $6,075,954. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.
A number of equities analysts recently commented on the company. Vetr downgraded Medtronic plc. from a “strong-buy” rating to a “buy” rating and set a $91.28 target price for the company. in a report on Monday, November 21st. Needham & Company LLC increased their price objective on Medtronic plc. from $84.00 to $91.00 and gave the stock a “buy” rating in a report on Tuesday, February 21st. Stifel Nicolaus decreased their price objective on Medtronic plc. from $91.00 to $81.00 and set a “hold” rating for the company in a report on Wednesday, November 23rd. Barclays PLC decreased their price objective on Medtronic plc. from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Wednesday, November 23rd. Finally, Oppenheimer Holdings Inc. decreased their price objective on Medtronic plc. from $94.00 to $84.00 and set an “outperform” rating for the company in a report on Wednesday, November 23rd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and sixteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $87.57.
Your IP Address:
About Medtronic plc.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic plc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic plc. and related companies with MarketBeat.com's FREE daily email newsletter.